T2 biosystems der game changer?! (Seite 178)
eröffnet am 12.01.20 23:54:10 von
neuester Beitrag 26.01.24 11:52:10 von
neuester Beitrag 26.01.24 11:52:10 von
Beiträge: 1.897
ID: 1.318.484
ID: 1.318.484
Aufrufe heute: 1
Gesamt: 143.274
Gesamt: 143.274
Aktive User: 0
ISIN: US89853L3024 · WKN: A3EU63 · Symbol: TTOO
2,9200
USD
+2,82 %
+0,0800 USD
Letzter Kurs 19:18:59 Nasdaq
Neuigkeiten
18.10.23 · wO Chartvergleich |
20.09.23 · wO Chartvergleich |
16.08.23 · Sharedeals |
16.08.23 · wO Chartvergleich |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 25,23 | +72,18 | |
| 4,7450 | +35,57 | |
| 2,4900 | +27,69 | |
| 9,3150 | +26,73 | |
| 4,8500 | +24,04 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,6100 | -15,26 | |
| 1,6100 | -18,27 | |
| 2,3100 | -25,00 | |
| 5,5000 | -32,10 | |
| 6,8250 | -62,10 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 63.528.935 von Roools am 01.05.20 13:29:52Was haltet ihr davon? Aus dem yahoo - Board. Dilution....ein Grund für den shares price???was meint Ihr?
Not sure how much people here are aware of this, but one of the reasons TTOO can't maintain any price gains is because it's flooding the market with more shares in order to raise funds (see SEC filing below) filed with the SEC as of April 8th. It was aiming to raise $95.0 million, which at current prices is almost 200 million shares. They were halfway through it at that point, so hopefully they'll stop slaughtering the stock price soon! I guess they needed to raise money any way they could - hopefully it is to fund rapid growth! If good news comes out in the near future, hopefully it will outweigh this planned dilution.
More promising is their recent partnership with Vizient, which serves 5000 not-for-profit hospitals/health organizations and can promote TTOO's products and services. TTOO reduced their headcount/sales staff earlier this year in a new approach to sales. I guess you could consider Vizient a channel partner that will, hopefully, be more effective than the past salesperson model. Good luck to all!
https://www.sec.gov/Archives/edgar/data/1492674/000119312520…
Up to $95,000,000
Common Stock
This supplement (this “Supplement”) supplements the prospectus supplement, dated March 9, 2020 (the “Prospectus Supplement”), relating to the offer and sale of shares of common stock, par value $0.001 per share, of T2 Biosystems, Inc. (the “Company”) from time to time through Canaccord Genuity LLC, or Canaccord, as the sales agent named therein. Sales of our common stock, if any, pursuant to this Supplement and the Prospectus Supplement will be made in sales deemed to be “at the market offerings” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, including sales directly on The Nasdaq Global Market or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. This Supplement should be read in conjunction with the Prospectus Supplement. Capitalized terms used and not defined herein shall have the meanings ascribed to such terms in the Prospectus Supplement.
This Supplement is being filed to reflect the amendment to the Equity Distribution Agreement by and between the Company and Canaccord Genuity LLC to increase the aggregate offering price of the offer and sale of shares of the Company’s common stock. Each reference to “$65.0 million” in the Prospectus Supplement is hereby amended to be “$95.0 million”. As of the date of this Supplement, we have sold 73,237,178 shares of our common stock with an aggregate offering price of approximately $48.1 million, leaving an aggregate offering price of up to approximately $46.9 million remaining under this Supplement.
The validity of the securities offered pursuant to this Supplement will be passed upon for us by Latham & Watkins LLP, New York, New York. Canaccord Genuity LLC is being represented in this offering by Cooley LLP, New York, New York.
Not sure how much people here are aware of this, but one of the reasons TTOO can't maintain any price gains is because it's flooding the market with more shares in order to raise funds (see SEC filing below) filed with the SEC as of April 8th. It was aiming to raise $95.0 million, which at current prices is almost 200 million shares. They were halfway through it at that point, so hopefully they'll stop slaughtering the stock price soon! I guess they needed to raise money any way they could - hopefully it is to fund rapid growth! If good news comes out in the near future, hopefully it will outweigh this planned dilution.
More promising is their recent partnership with Vizient, which serves 5000 not-for-profit hospitals/health organizations and can promote TTOO's products and services. TTOO reduced their headcount/sales staff earlier this year in a new approach to sales. I guess you could consider Vizient a channel partner that will, hopefully, be more effective than the past salesperson model. Good luck to all!
https://www.sec.gov/Archives/edgar/data/1492674/000119312520…
Up to $95,000,000
Common Stock
This supplement (this “Supplement”) supplements the prospectus supplement, dated March 9, 2020 (the “Prospectus Supplement”), relating to the offer and sale of shares of common stock, par value $0.001 per share, of T2 Biosystems, Inc. (the “Company”) from time to time through Canaccord Genuity LLC, or Canaccord, as the sales agent named therein. Sales of our common stock, if any, pursuant to this Supplement and the Prospectus Supplement will be made in sales deemed to be “at the market offerings” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, including sales directly on The Nasdaq Global Market or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. This Supplement should be read in conjunction with the Prospectus Supplement. Capitalized terms used and not defined herein shall have the meanings ascribed to such terms in the Prospectus Supplement.
This Supplement is being filed to reflect the amendment to the Equity Distribution Agreement by and between the Company and Canaccord Genuity LLC to increase the aggregate offering price of the offer and sale of shares of the Company’s common stock. Each reference to “$65.0 million” in the Prospectus Supplement is hereby amended to be “$95.0 million”. As of the date of this Supplement, we have sold 73,237,178 shares of our common stock with an aggregate offering price of approximately $48.1 million, leaving an aggregate offering price of up to approximately $46.9 million remaining under this Supplement.
The validity of the securities offered pursuant to this Supplement will be passed upon for us by Latham & Watkins LLP, New York, New York. Canaccord Genuity LLC is being represented in this offering by Cooley LLP, New York, New York.
https://www.wallstreet-online.de/nachricht/12048098-t2-biosy…
Mr. Sperzel brings a wealth of leadership and operating experience to T2 Biosystems. He most recently served as President and CEO of Chembio Diagnostics, Inc. (NASDAQ: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, from 2014 through 2020. Under his leadership, Chembio established direct U.S. and international sales teams resulting in significant growth, entered collaborations with two major pharmaceutical companies to create additional revenue opportunities, and made commercial investments in Latin America and Southeast Asia. Prior to Chembio, Mr. Sperzel served as President and CEO of ITC Medical, a privately-held point-of-care diagnostics company owned by Warburg-Pincus. Previously, Mr. Sperzel held executive and commercial leadership positions at Axis-Shield (Abbott), Bayer Diagnostics (Siemens), Instrumentation Laboratory, and Boehringer Mannheim (Roche). Mr. Sperzel holds a Bachelor of Science in Business/Management from Plymouth State University
T2 Biosystems Appoints Industry Veteran John Sperzel as Chief Executive Officer | wallstreet-online.de - Vollständiger Artikel unter:
sehr erfahrener Mann den man sich da Anfang des Jahres geholt hat.
Mr. Sperzel brings a wealth of leadership and operating experience to T2 Biosystems. He most recently served as President and CEO of Chembio Diagnostics, Inc. (NASDAQ: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, from 2014 through 2020. Under his leadership, Chembio established direct U.S. and international sales teams resulting in significant growth, entered collaborations with two major pharmaceutical companies to create additional revenue opportunities, and made commercial investments in Latin America and Southeast Asia. Prior to Chembio, Mr. Sperzel served as President and CEO of ITC Medical, a privately-held point-of-care diagnostics company owned by Warburg-Pincus. Previously, Mr. Sperzel held executive and commercial leadership positions at Axis-Shield (Abbott), Bayer Diagnostics (Siemens), Instrumentation Laboratory, and Boehringer Mannheim (Roche). Mr. Sperzel holds a Bachelor of Science in Business/Management from Plymouth State University
T2 Biosystems Appoints Industry Veteran John Sperzel as Chief Executive Officer | wallstreet-online.de - Vollständiger Artikel unter:
sehr erfahrener Mann den man sich da Anfang des Jahres geholt hat.
Trading Spotlight
So bin jetzt auch mal zu 0,50 rein.
Antwort auf Beitrag Nr.: 63.514.595 von BTRRR am 30.04.20 11:59:33
Würde mich auch interessieren. Bin hier auch schon länger dabei und warte auf die richtigen News...
Danke!
Zitat von BTRRR: @schaeffi, klar mache dir eine PN!
Würde mich auch interessieren. Bin hier auch schon länger dabei und warte auf die richtigen News...
Danke!
Antwort auf Beitrag Nr.: 63.514.364 von timlisa2016 am 30.04.20 11:45:50sicherlich ist dies keine Aktie für Leute die im Supermarkt paketweise Klopapier nachhause schleppen.
Antwort auf Beitrag Nr.: 63.514.364 von timlisa2016 am 30.04.20 11:45:50Informiere dich doch selber einmal! Viele machen es sich schon sehr einfach!
@schaeffi, klar mache dir eine PN!
@schaeffi, klar mache dir eine PN!
Antwort auf Beitrag Nr.: 63.512.756 von bmuesli am 30.04.20 10:26:09Wieviel Cash hat T2 noch? Die burn rate ist ja schon recht hoch pro Quartal....., wielange reicht das Geld noch...., müssen die nicht langsam auch wieder über einen Dollar? Nasdaq regeln und so?
Durchsuchen
18.10.23 · wO Chartvergleich · Bayer |
20.09.23 · wO Chartvergleich · Borussia Dortmund |
16.08.23 · Sharedeals · T2 Biosystems |
16.08.23 · wO Chartvergleich · AVZ Minerals |